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Abstract
Background: Tissue-specific gene deletion has proved informative in the analysis of pain pathways. Advillin has
been shown to be a pan-neuronal marker of spinal and cranial sensory ganglia. We generated BAC transgenic mice
using the Advillin promoter to drive a tamoxifen-inducible CreERT2 recombinase construct in order to be able to
delete genes in adult animals. We used a floxed stop ROSA26LacZ reporter mouse to examine functional Cre
expression, and analysed the behaviour of mice expressing Cre recombinase.
Results: We used recombineering to introduce a CreERT2 cassette in place of exon 2 of the Advillin gene into a
BAC clone (RPCI23-424F19) containing the 5’ region of the Advillin gene. Transgenic mice were generated using
pronuclear injection. The resulting AvCreERT2 transgenic mice showed a highly specific expression pattern of Cre
activity after tamoxifen induction. Recombinase activity was confined to sensory neurons and no expression was
found in other organs. Less than 1% of neurons showed Cre expression in the absence of tamoxifen treatment.
Five-day intraperitoneal treatment with tamoxifen (2 mg per day) induced Cre recombination events in ≈90% of
neurons in dorsal root and cranial ganglia. Cell counts of dorsal root ganglia (DRG) from transgenic animals with or
without tamoxifen treatment showed no neuronal cell loss. Sensory neurons in culture showed ≈70% induction
after 3 days treatment with tamoxifen. Behavioural tests showed no differences between wildtype, AvCreERT2 and
tamoxifen-treated animals in terms of motor function, responses to light touch and noxious pressure, thermal
thresholds as well as responses to inflammatory agents.
Conclusions: Our results suggest that the inducible pan-DRG AvCreERT2 deleter mouse strain is a useful tool for
studying the role of individual genes in adult sensory neuron function. The pain phenotype of the Cre-induced
animal is normal; therefore any alterations in pain processing can be unambiguously attributed to loss of the
targeted gene.
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Background
Transgenic mice continue to be an important tool for
the study of gene function in pain research. By 2007,
over 400 papers had already been published with statis-
tically significant behavioural pain phenotypes in trans-
genic knockout mice [1]. While these papers
demonstrate the usefulness of transgenic knockout
studies, some also reveal the drawbacks to this method.
Ablation mutations introduced in the germ line may
result in complications including early lethality, develop-
mental compensatory mechanisms, and complex pheno-
types when working with a pleiotropic gene [2,3].
Tissue-specific gene targeting may prevent early lethal-
ity, but temporal control would clarify the issue of com-
pensation by other genes and negate confounding
developmental roles the gene may play. Inducible tissue-
specific gene targeting would thus be of great use in stu-
dies of gene function. Such a system has been previously
developed using a version of the Cre-loxP system [4-7].
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ments when flanked with 34-bp loxP sites. Bacterioph-
age-produced Cre recombinase recognizes loxP sites and
catalyzes molecular recombination between those sites.
When a tissue-specific promoter drives Cre recombi-
nase, the DNA recombination is restricted to that tissue
[8].
In a modification of the Cre-loxP system Cre recombi-
nase is fused to a mutated ligand-binding domain of the
human estrogen receptor (ER) producing CreER, which
is inducible in the presence of an estrogen agonist [9]. A
more efficient version of the CreER fusion protein is
CreERT2, which contains 3 mutations in the human ER
such that the complex is activated by the synthetic
estrogen-like agonist tamoxifen, but not by endogenous
estrogens [5].
While transgenic, linkage mapping and microarray
studies have put forward many pain-relevant gene candi-
dates [1,10,11], these genes are often widely expressed in
both neuronal and non-neuronal tissues, making their
specific function in pain pathways particularly challen-
ging to ascertain. Peripheral sensory neuron specific
gene deletion would therefore help to clarify the role of
specific genes in pain pathways. To accomplish this, a
peripheral sensory neuron specific promoter was used to
drive CreERT2 expression. Advillin (also known as Per-
vin) is an actin-binding protein of gelsolin family found
almost exclusively in peripheral sensory neurons [12-14]
making it particularly relevant to nociception and pain
research [15-17]. An Advillin knock-in Cre has been
generated and is capable of deleting genes in all sensory
neurons [18]. By placing CreERT2 under the control of
the Advillin promoter, one can manipulate genes speci-
fically in peripheral sensory neurons. Here, we describe
the production and characterisation of Advillin-CreERT2
(AvCreERT2) mice in terms of expression patterns and
the efficiency of recombination. AvCreERT2 and tamox-
ifen treatment are also shown to have no behavioural
effects in various pain models.
Results and discussion
Generation of AvCreERT2 transgenic mice
We generated AvCreERT2 transgenic mice using a con-
struct obtained by recombineering protocol [19] (Figure
1A). BAC clone RPCI23-424F19 containing part of the
Advillin gene was used as a template to prepare a tar-
geting construct. The shuttle vector for recombineering
w a sm a d eb yi n s e r t i n gt h e5 ’-homology arm (0.45 kb)
and the 3’-homology arm (0.3 kb) flanking exon 2 of the
Advillin gene into a vector containing CreERT2 and a
Kanamycin cassette. The Kanamycin resistance gene in
the cassette was flanked by FRT sites (recognition sites
for Flp-recombinase). In the resulting shuttle vector we
fused the CreERT2 sequence with the start codon in the
exon 2 of the Advillin gene. The completed shuttle con-
struct was sequenced and the targeting cassette was iso-
lated from the plasmid by AscI/PacI digest.
EL250 E. coli cells transformed with the BAC clone
were co-transformed with the shuttle targeting construct
and recombination was induced by heat-shock. The
induced bacterial clones were isolated by growing them
on Kanamycin-containing plates. The Kanamycin resis-
tance cassette was removed by inducing Flp-recombi-
nase expression by arabinose. The final construct was
verified by PCR and analytical restriction digests by
NotI and PacI. The resulting BAC containing the target-
ing cassette was used for pronucleus injection.
We obtained 8 founders verified by PCR analysis that
transmitted CreERT2 to their offspring. Primers for
PCR analysis are described in Materials and Methods
and their verification is presented in Figure 1B. The off-
spring of the founders was crossed with ROSA26RLacZ
mice and their various tissues were stained with X-gal
following tamoxifen injections. The offspring of the
founder A displayed the most profound staining in the
DRG and was used for all the subsequent experiments.
To estimate the copy number of the transgenes in the
offspring of founder A, we performed a Southern blot
on genomic DNA from isolated from tail snips. The
DNA was digested with HindIII and hybridized with the
5’ homology arm probe. This probe recognizes both the
wildtype and transgene variants. The resulting wildtype
band was 7.4 kb and the transgene band was 3.6 kb
(Figure 1C). We scanned the relative densities of the
bands using ImageJ software and found that after back-
ground subtraction the value of transgene band is
roughly 5 times higher than the wildtype band. Given
that the wildtype band corresponds to 2 copies of Advil-
lin per genome, we estimate that the offspring of foun-
der A had about 10 copies of BAC integrated into the
genome.
Expression pattern of AvCreERT2 in DRG neurons
To determine whether the Advillin promoter driven Cre
expression pattern recapitulates the expression pattern
of wildtype Advillin we crossed AvCreERT2 mice with
the Rosa26LacZ mouse strain [20]. In the Rosa26LacZ
strain floxed polyadenylation signal blocks the expres-
sion of b-galactosidase. Introduction of Cre in a tissue-
specific manner leads to the synthesis of functional b-
galactosidase, which is detectable with X-gal staining
[20].
Tamoxifen was injected intraperitoneally (ip) for 5
consecutive days, 2 mg per day (10 mg total dose). The
control animals were injected with vehicle only. Animals
were euthanized and perfused with 4% paraformalde-
hyde. DRG were isolated and sectioned. The sections
were stained with X-gal. Figure 2A shows DRG sections
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Page 2 of 13Figure 1 Generation of tamoxifen inducible Advillin Cre mouse. A - Diagram of the wt Advillin allele and the targeting construct. CreERT2 is
inserted downstream of the initiation codon of Advillin. The construct also contained a Kanamycin selection gene that was excised from the BAC
by Flp-recombination. B - Primer validation for screening of transgenic animals. AF - Advillin forward primer, AR - Advillin reverse primer, CF - Cre
forward primer, CR - Cre reverse primer. The expected sizes of the PCR fragments are indicated. C - Southern blot with tail genomic DNA
digested with HindIII and hybridized with the 5’homology arm probe. The bands for wildtype gene (wt) and transgene (tg) are indicated.
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Figure 2 Tamoxifen induces recombination in the DRG of adult AvCreERT2 mouse. Animals were injected (ip) for 5 consecutive days (2 mg
per day). A - X-gal staining of adult DRG neurons from induced and un-induced mice. Neutral red was used for counterstaining. B -
Quantification of recombination events in DRG of untreated and tamoxifen-treated animals. Data are presented as mean ± SEM. Statistical
analysis - unpaired T-test, p ≤ 0.01. Scale bars = 40 μm.
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Page 4 of 13from tamoxifen-treated mice, where most neurons show
positive blue staining whilst DRG sections from control
mice show less than 1% Cre positive staining. This is
probably due to spontaneous Cre activation. Quantifica-
tion of results from three independent experiments is
shown in Figure 2B. DRG sections from tamoxifen
injected mice show on average 89% of Cre positive
staining whereas control animals show 0.95% Cre posi-
tive blue staining. It is important to note that in all
DRG sections from tamoxifen-treated mice, the percen-
tage of cells with Cre positive staining was never lower
than 82% and the maximum recorded staining was
99.2%. These results demonstrate that AvCreERT2
transgenic mice are a useful pan-DRG inducible deleter
strain.
To assess the types of sensory neurons that express
the transgene we labelled DRG sections with antibodies
against peripherin (Figure 3B in green) and neurofila-
m e n t - 2 0 0( F i g u r e3 Bi nr e d ) .T h es a m es e c t i o n sw e r e
stained with X-gal to characterize Cre-recombinase
activity (Figure 3A). The number of peripherin and neu-
rofilament-200 expressing neurons in tamoxifen-treated
AvCreERT2/Rosa26LacZ mice correlates to historical
data from wildtype mice [21] (Figure 3C). This indicates
that transgene insertion and/or tamoxifen treatment
does not change the relative proportion of sensory
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Figure 3 Co-localization of X-gal staining with peripherin and NF200 positive neurons in the dorsal root ganglia of the adult
AvCreERT2 mice. A - X-gal (transmitted light) and B. - Anti-peripherin (green) and anti-NF200 staining (red). C - Tamoxifen treatment does not
alter the composition of DRG. White bars - wt, Grey bars - uninjected AvCreERT2 animals, Black bars - AvCreERT2 animals injected with tamoxifen
(2 mg per day, 5 days). D - Quantification of the total number of neurons per DRG of wildtype and AvCreERT2 mice (untreated and injected
with tamoxifen). Data are presented as mean ± SEM. Scale bars = 40 μm.
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Page 5 of 13neurons. We further investigated the actual numbers of
sensory neurons per DRG and compared it to historical
data from wildtype mice (Figure 3D). No differences
were found in the actual numbers of neurons in the
DRG of wildtype animals, untreated and tamoxifen-trea-
ted AvCreERT2 transgenic animals.
Our data suggest that the insertion of the AvCreERT2
transgene and tamoxifen treatment does not alter the num-
ber or the relative proportion of sensory neurons in DRG.
We also performed X-gal staining on a variety of tissue
sections from tamoxifen-treated mice (results not shown).
These tissues included brain, liver, lungs, kidney, olfactory
epithelium, adrenal glands, skin etc. No positive Cre stain-
ing was observed. These results prove that AvCreERT2
transgene expression recapitulates the previously reported
expression pattern of wildtype Advillin [13,22].
Tamoxifen induces Cre-expression during embryonic
development
To assess the possibility of Cre induction during embryo-
nic development we set up timed matings of AvCreERT2/
ROSA26LacZ mice. It has been shown that expression of
Advillin starts at day E11.5 in trigeminal ganglia. In DRG
neurons Advillin staining is clearly visible at day E12.5
[22]. We started to inject pregnant mice at day E12.5 for 5
consecutive days with 2 mg of tamoxifen per day. Embryos
were harvested at E18.5 and stained with X-gal. Embryos
from tamoxifen-treated mice displayed clear positive stain-
ing in DRG and trigeminal ganglia (Figure 4). All other
organs showed no positive Cre staining. Untreated
embryos displayed no positive Cre staining. These data are
in agreement with the previously published data on the
Advillin gene expression [22].
A 
B 
Figure 4 Tamoxifen induces Cre-expression during embryonic development. A - E18.5 AvCreERT2-positive embryos from tamoxifen treated
pregnant females (2 mg per day, 5 days). B - E18.5 AvCreERT2-positive embryos from vehicle treated pregnant females.
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We also investigated the ability of tamoxifen to induce
Cre recombination in cultured DRG neurons from
AvCreERT2/ROSA26LacZ mice. Cell cultures were trea-
ted with 4-Hydroxytamoxifen (4-OHT) for 3 consecutive
days. The cell cultures were treated with 1 μM4 - O H T
on the first day and with 2 μMo f4 - O H To nt h et w o
subsequent days (Figure 5A). We also tried 10 μM4 -
OHT treatment but found it to be toxic. The neurons
were fixed and stained with X-gal and antibodies against
peripherin and neurofilament-200. The results were
quantified and are presented in Figure 5B. Tamoxifen
induces Cre recombination in about 70% of cultured
DRG neurons. Virtually no Cre positive staining was
observed in the untreated cultures.
AvCreERT2 expressing mice and tamoxifen-treated show
normal acute and inflammatory pain behaviour
Motor function was assessed using the Rotarod test. The
mean time spent on the apparatus was not significantly
different for AvCreERT2 mice (Figure 6Aa) or following
tamoxifen treatment (Figure 6Ba). Mechanical thresh-
olds were assessed using the von Frey and Randall-
Selitto tests. The mean response thresholds for both
tests were not significantly different for AvCreERT2
mice (Figure 6Ab&6Ac) or following tamoxifen treat-
ment (Figure 6Bb&6Bc). This suggest both responses to
light touch and noxious pressure are unaffected by
AvCreERT2 or tamoxifen. Thermal thresholds were
assessed using the Hargreaves’, hot plate (50°C & 55°C)
and acetone test. The mean withdrawal latencies to both
the Hargreaves’ and hot plate tests were not significantly
different for AvCreERT2 mice (Figure 6Ad&6Ae) or fol-
lowing tamoxifen treatment (Figure 6Bd&6Be). This
suggests that both spinal reflexes and supra-spinal pro-
cessing of noxious heat are unaffected by AvCreERT2 or
tamoxifen [23]. Similarly the mean response times to
the acetone test was not significantly different for
AvCreERT2 mice (Figure 6Af) or following tamoxifen
treatment (Figure 6Bf). This suggests that processing of
noxious cooling stimuli are unaffected by AvCreERT2 or
tamoxifen. Finally, the behavioural responses to both 5%
formalin and CFA intraplantar injection were not signif-
icantly different for AvCreERT2 mice or following
tamoxifen treatment (Figure 7).
Conclusions
We generated a transgenic AvCreERT2 mouse line that
displays functional expression of Cre recombinase after
tamoxifen induction. We described molecular and beha-
vioural characterization of this line. The Advillin pro-
moter drives the expression of Cre recombinase with
the same characteristics as the wildtype Advillin gene.
The expression of this gene is specific to sensory
neurones making it very useful for creating pan-DRG
deleter mouse strains.
The results described in this paper show that we are
able to induce Cre expression in 89% of DRG neurons
in vivo (5 injections, 2 mg per day) and in 70% of neu-
rons in vitro (4-OHT treatment for 3 days). We com-
pared the proportion of anti-peripherin and anti-
neuropfilament-200 stained neurons in AvCreERT2
DRG sections with wildtype DRG sections and found no
differences. We also found no differences in the actual
numbers of DRG neurons in wildtype animals, and
untreated and tamoxifen treated AvCreERT2 transgenic
animals.
These results suggest that the neuronal composition of
AvCreERT2 DRG mice is the same as wildtype mice.
Behavioural studies of wildtype, untreated and tamoxifen
treated and AvCreERT2 mice show that motor function,
responses to light touch and noxious pressure, as well
as thermal thresholds do not differ significantly between
these animals.
Our results suggest that we generated an inducible
pan-DRG deleter mouse strain that can be used to study
the role of individual genes in pain transduction in vivo
and their role in cell excitability in vitro. Thus this
mouse strain may provide mechanistic insights that
identify new therapeutic pain targets.
Methods
Animals
All tests were approved by the United Kingdom Home
Office Animals (Scientific Procedures) Act 1986. Experi-
ments were conducted using both male and female lit-
termate mice, all of which were at least 6 weeks old
when tested. The same observer performed all experi-
ments and was blind to the genotype of the animals.
Generation of transgenic construct
To create the construct for production of the transgenic
AvCreERT2 mouse line we used a recombineering tech-
nique [19]. The CreERT2 containing plasmid which also
contained a FRT flanked Kanamycin selection cassette
was a gift from Prof Chambon [9].
Briefly, the start codon of Advillin is located in exon 2
o ft h eg e n e .T h e5 ’ homologous arm of the construct
(0.45 kb) was amplified from a BAC containing exon 2
of the Advillin gene and cloned into the AscI/SalI
restriction sites of the CreERT2 vector. The 3’homolo-
gous arm (0.3 kb) was amplified from the same BAC
and cloned into the PacI/EagI restriction sites of the
CreERT2 vector. The completed shuttle construct was
sequenced and the targeting cassette was isolated from
the plasmid by AscI/PacI digest.
EL250 E. coli cells were transformed with the BAC
containing the Advillin gene. Isolated BAC DNA from
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Figure 5 4-OHT induces Cre-expression in cell culture of neurons from dorsal root ganglia of AvCreERT2 mice. A - X-Gal, anti-peripherin
(green) and anti-NF200 (red) staining of 4-OHT treated and uninduced cell cultures from DRG. Arrows indicate X-gal stained neurons. Note the
punctuate nature of X-gal staining. B - Quantification of recombination events in untreated and 4-OHT treated cultures of neurons from DRGs.
Data are presented as mean ± SEM. Statistical analysis - unpaired T-test, p ≤ 0.01. Scale bars = 40 μm.
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Figure 6 AvCreERT2 expression or tamoxifen treatment (10 mg) does not affect acute nociceptive responses. A - Behavioural responses
of AvCreERT2 and littermate mice to Aa) Rotarod (AvCreERT2 N = 13, littermate N = 11), Ab) von Frey (AvCreERT2 N = 13, littermate N = 11), Ac)
Randall-Selitto (AvCreERT2 N = 8, littermate N = 8), Ad) Hargreaves’ (AvCreERT2 N = 13, littermate N = 11), Ae) (AvCreERT2 N = 7, littermate N =
8) Af) Acetone (AvCreERT2 N = 8, littermate N = 8). No significant difference was found (t-test). Data are expressed as mean ± SEM. B - C57BL/6
mice received a five-day course of tamoxifen (2 mg/0.2 ml per day), or vehicle (0.2 ml per day). Responses to Ba) Rotarod (tamoxifen N = 12,
vehicle N = 11) Bb) von Frey (tamoxifen N = 12, vehicle N = 11). Bc) Randall-Selitto (tamoxifen N = 6, vehicle N = 5) Bd) Hargreaves’ (tamoxifen
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Figure 7 AvCreERT2 expression or tamoxifen (10 mg) treatment does not affect inflammatory nociceptive responses. A - Behavioural
responses of AvCreERT2 and littermate mice to inflammatory pain tests Aa) Pain behaviour of AvCreERT2 (N = 6) & littermate (N = 6) mice after
intraplantar injection of 20 μl of 5% formalin. Ab) Time spent licking/biting the injected hindpaw in phase I (1-10 min) and phase II (10-60 min)
(AvCreERT2 N = 6, littermate N = 6), Ac) Mechanical allodynia following intraplantar injection of 20 μl of CFA (AvCreERT2 N = 7, littermate N =
6), Ad) Thermal hyperalgesia after intraplantar injection of 20 μl of CFA (AvCreERT2 N = 7, littermate N = 6). No significant difference was found
(Two-way repeated measures ANOVA). Data are expressed as mean ± SEM. B - Behavioural responses of C57BL/6 mice injected with a five-day
course of tamoxifen (2 mg/0.2 ml per day), or vehicle (0.2 ml per day) to inflammatory pain tests. Ba) Pain behavior of tamoxifen-treated (N = 6)
& vehicle-treated (N = 6) mice after intraplantar injection of 20 μl of 5% formalin. Bb) Time spent licking/biting the injected hindpaw in phase I
(1-10 min) and phase II (10 -60 min) (tamoxifen N = 6, vehicle N = 6), Bc) Mechanical allodynia following intraplantar injection of 20 μl of CFA
(tamoxifen N = 6, vehicle N = 6), Bd) Thermal hyperalgesia after intraplantar injection of 20 μl of CFA (tamoxifen N = 6, vehicle N = 6). Animals
were examined 7 days following tamoxifen/vehicle treatment. No significant differences were found (Two-way repeated measures ANOVA). Data
are expressed as mean ± SEM.
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Page 10 of 13the individual clones was checked by restriction analysis
followed by pulse-field gel electrophoresis. Only the
clones displaying the correct pattern of the restriction
fragments were used for the recombineering procedure.
The correct bacterial clones were co-transformed by
shuttle construct and recombination was induced by
incubating the bacteria at 42°C for 15 minutes. The
induced bacterial clones were isolated by growing them
on Kanamycin containing plates. The Kanamycin resis-
tance cassette was removed by inducing Flp-recombi-
nase expression by arabinose. The final construct was
verified by PCR and analytical restriction digests using
NotI and PacI.
Transgenic mouse production and screening
The resulting BAC was isolated, digested by Not I, gel
purified and used for the oocyte microinjection. The
founders were screened by PCR and Southern blot. The
primers for PCR are as follows:
AdF:GACAGATTATCTGCAATCTCTCTAAG, AdR:
AGAGCACAGAGCCACCCTCGAGAC, CREF:GGCCT
GGTCTGGCCACTCTGCCAG, CRER:GTTCCTGA
TGTCCTGGCATCTGTC.
The products of PCR reactions are AdF/AdR - 0.95 kb
(wt) and 3.39(tg), AdF/CreR - 1.027 kb and CreF/AdR -
1.99 kb. The products were resolved on 1% agarose gel,
stained with ethidium bromide and photographed.
Southern blot analysis
Genomic DNA was extracted from tail snips [24]. The 5’
probe which recognizes both the wildtype gene and
transgene was amplified from BAC using the following
primers Avil5HS: GACGGCGCGCCCTCAGGAATATG
TGTTGCCTTTC; Avil5HAS: TCTGTCGACCATAG
TGGCTGTCTTCCTGGAAC.
Southern blot analysis with HindIII digested genomic
DNA produced a 7.4 kb wildtype band and a 3.6 kb
transgene band (Figure 1C).
Tamoxifen treatment
Tamoxifen (Sigma T5648) and 4-OHT (Sigma H7904)
solutions were prepared according to a previously
described protocol [9]. Eight week old AvCreERT2/
ROSA26LacZ mice were injected with 2 mg of tamoxi-
fen (ip) daily for 5 consecutive days. Two days after the
last injection mice were euthanized and DRG were col-
lected for further analysis. To characterize Cre induction
during embryonic development, pregnant AvCreERT2/
ROSA26LacZ mice were injected with either 2 mg of
tamoxifen or vehicle daily for 5 consecutive days starting
a td a yE 1 2 . 5 .O nd a yE 1 8 . 5t h em i c ew e r ee u t h a n i z e d
and the embryos were collected for further analysis. All
embryos were genotyped.
Cultured DRG neurons were treated with 4-OHT for
3 days (1 μMo nt h ef i r s td a ya n d2μM the following
two days). The neurons were fixed and analyzed the day
after the final treatment.
DRG cell culture
AvCreERT2/ROSA26LacZ animals were killed by inhala-
tion of a rising concentration of CO2 followed by cervi-
cal dislocation, and 30-40 DRG were dissected from
each. Ganglia were digested in collagenase (Type XI, 0.6
mg/ml, Sigma), dispase (3.0 mg/ml, Sigma), and glucose
(1.8 mg/ml) in Ca
2+, Mg
2+ free PBS for 40 min prior to
mechnical trituration. Cells were then resupended in
Dulbecco’s modified Eagle’s medium (Gibco) containing
10% fetal bovine serum (Gibco), 10,000 i.u./ml penicil-
lin-streptomycin (Gibco), and 100 ng/ml nerve growth
factor (Sigma), and plated on 13-mm cover slips coated
with poly-L-lysine.
Immunohistochemistry
The staining was performed as previously described [25].
Briefly, following the tamoxifen treatment, the DRGs
were isolated and immediately frozen in OCT (O.C.T.
Compounds, BDH) on dry ice. 12 μm cryosections were
dried at room temperature for 30 min and then fixed
with 4% PBS-buffered paraformaldehyde solution for 10
m i no ni c e .A f t e rt h r e ew a s h e si nP B S ,s e c t i o n sw e r e
incubated for 30 min in 10% goat serum diluted in PBS
containing 0.3% Triton X-100 (PBST), and for 1 h at
room temperature in a 1:500 dilution of an anti periph-
erin monoclonal antibody (P5117, Sigma) and 1:200
dilution of an anti N-200 polyclonal antibody (N4142,
Sigma). Following three washes in PBST, the sections
were incubated for 1 h in a 1:500 dilution of Alexa
Fluor 488 goat anti-mouse IgG (A-11017, Molecular
Probes) and 1:1,000 dilution of Alexa Fluor594 goat
anti-rabbit IgG (A-11037, Molecular Probes). After three
washes in PBST, the sections were mounted in CITI-
Flour solution and analysed using a fluorescent
microscope.
X-gal staining
After fixation with 4% PBS-buffered paraformaldehyde
or after immunohistochemistry, DRG sections were
washed three times with PBS and then incubated over-
night in X-gal solution at 35°C. For cultured DRG neu-
rons, the slides were fixed with 2% PBS-buffered
formaldehyde containing 0.25% glutaraldehyde for 15
min at room temperature, and then stained with X-gal
solution at 35°C overnight. Sections or slides (cultured
DRG neurons) were counterstained with 1% neutral red,
dehydrated with ethanol, and cleared with Histo-ClearII
and mounted with DePex mounting medium (BDH).
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punctate in appearance, but homogeneous in perfused
DRG sections and in cultured DRG neurons.
The staining of the E18.5 embryos was performed as
follows. The embryos were isolated from pregnant
females killed by CO2 inhalation and cervical disloca-
tion. The embryos were placed immediately into 1:40
dilution of sodium pentobarbitone in PBS for 5 min at
room temperature. This was followed by 3 washes with
PBS and the embryos were skinned to allow better
penetration of staining solutions. Tail biopsies were
taken for genotyping. The embryos were fixed at room
temperature for 2 hours, washed and left over night in
the LacZ staining solution at room temperature. The
next day embryos were washed with PBS and were
cleared by incubating for 24 hours at 4°C in the follow-
ing solutions: 70% ethanol, 100% methanol, fresh 100%
methanol and benzyl benzoate:benzyl alcohol (2:1).
Cleared embryos were photographed and analyzed.
Behavioural studies
The motor coordination of transgenic and wildtype mice
was assessed using the Rotarod test [26] before testing
nociceptive responses.
Thermal nociception
Thermal nociceptive thresholds were measured using
the paw-withdrawal latency according to the method
described by [27], with minor modifications. As well as
the hot-plate test (50 & 55°C) originally described by
[28] and later modified by [29]. Behavioural responses
to cooling (approx. 10-15°C) were assessed using the
acetone test, as described by [30].
Mechanical nociception
Mechanical nociceptive thresholds were measured using
a modified version of the Randall-Selitto test [31] that
applies pressure to the tail via a 3 mm
2 blunt probe
[32]. Touch perception thresholds were measured using
the up-down method for obtaining the 50% threshold
using von Frey hairs as described by [33].
List of abbreviations used
DRG: dorsal root ganglion; AvCreERT2: Advillin-CreERT2; BAC: bacterial
artificial chromosome; 4-OHT: 4-hydroxytamoxifen.
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